Juno Therapeutics will use the reagents to produce its chimeric antigen receptor T-cell (CAR T) therapies.
Juno Therapeutics has signed a seven-year, nonexclusive license and supply agreement with Thermo Fisher Scientific for use of Thermo Fisher's Cell Therapy Systems (CTS) activation reagents in the manufacture of its chimeric antigen receptor T-cell (CAR T) therapies.
Through this transaction, Juno has purchased the right to use CTS Dynabeads CD3/CD28 magnetic beads in the clinical- and commercial-scale production of its CAR T therapies. The proprietary, scalable CTS Dynabead platform is used around the world in the research, development, and commercialization of other CAR T cell therapies. The scalability allows for rapid scale-up of processes with high reproducibility at different scales. The CTS Dynabeads are used to activate and expand genetically engineered T cells.
"Juno aims to manufacture best-in-class CAR T therapies to help as many patients as we can," said Ann L. Lee, Juno's executive vice president of Technical Operations. "Thermo Fisher's technology will help us do that and deliver on our promise to patients."
Juno’s pipeline consists of several investigational CAR T cell product candidates targeting a variety of cancers, including non-Hodgkin lymphoma, pediatric acute lymphoblastic leukemia, multiple myeloma, acute myeloid leukemia, pediatric neuroblastoma, non-small cell lung cancer, other lung cancers, mesothelioma and ovarian and breast cancer.
